Hem/Onc @Point of Care 对比 Hematology app 的使用情况和统计数据
Hematology/Oncology @Point of Care™ is a clinical decision-making mobile platform. It provides a streamlined clinical decision support tool for clinicians to obtain content when it is needed, keep track of their patients—enabling better decisions, better outcomes, and better care.
Featuring @sk Cognitive AI, clinicians use Hematology/Oncology @Point of Care to easily access curated, evidence-based, and disease-specific medical content. Clinicians navigate content by asking voice-enabled natural language questions. The @sk Cognitive, confidence-rated answers happen more quickly to efficiently incorporate best treatment options and decisions are made faster to improve patient outcomes at the point of care.
Hematology/Oncology @Point of Care is designed to:
• Support discovery and practice change
• Provide relevant, evidence-based disease-specific medical content
• Improve patient outcomes at the point of care
Features:
• Continually updated content
• Topics in diagnosis, treatment, and care management developed with expert physician authors
• Case studies, videos, and interviews
• Access to actionable patient-recorded data
• Detailed reference list with access to original sources
• Continuing medical education credit (CME/CE)
• Surveys and peer polling
• Patient education resources to share with patients
• Receive detailed information regarding your patients' health such as: Medications and treatments; Symptoms and side effects; Charts that record test results, medication adherence, and more
• Voice-activate commands for Watson, Patient Access and Clinical resources
• Read-aloud feature for hands-free listening to medical texts
• App Prescriber lets you prescribe one of our many patient apps to your patients
- Apple 应用商店
- 免费
- 医疗
商店排名
- -
The HematologyApp is intended for use by medical professionals only. It offers a vast amount of hematology related content with risk calculators, diagnostic criteria, differential diagnostic lists, official guidelines, an extensive bone marrow and peripheral blood morphology atlas and a clinical study finder.
Dr. JJWM Janssen, MD PhD and the Apps for Care and Science Foundation have used the highest standards to select and program the HematologyApp content in a way that will help hematologists to perform their everyday work in a more efficient way and to improve quality of patient care.
As medicine is an ever-evolving science and standards and practices in medicine may rapidly change as new data become available, the individual medical professional should therefore consult a variety of sources. For this reason, please make sure to have the automatic app update option installed on your smartphone. Only the most current release of the HematologyApp should be consulted when information is sought; do not rely on older versions.
Although we are doing our utmost best to keep the information in this App up-to-date, when prescribing medications according to the Hematology App, the user is advised to check the product information sheet accompanying each drug to verify conditions of use and identify any changes in dosage schedule or contraindications, particularly if the agent to be administered is new, infrequently used or has a narrow therapeutic range. The information provided in the HematologyApp may be changed without notice and is not guaranteed to be complete, error-free, correct or up-to date and is no substitute for individual patient assessment based upon the healthcare provider's examination of each patient and consideration of laboratory data and other factors unique to the patient.
The HematologyApp should be used as a tool to help the user reach diagnostic and treatment decisions, bearing in mind that individual and unique circumstances may lead the user to reach decisions not presented in this App.
Disclaimer for non-medical professional users: Please be sure to seek a doctor’s advice in addition to using this app and before making any medical decisions.
- Apple 应用商店
- 免费
- 医疗
商店排名
- -
Hem/Onc @Point of Care VS. 
Hematology app十二月 12, 2024